Excellence in Product Development Shapes Beverage Innovations in Europe, According to NielsenIQ BASES Annual Breakthrough Innovations Report
9.11.2021 09:01:00 EET | Business Wire | Press release
As beverage innovations sweep up the most accolades across Europe in NielsenIQ BASES Breakthrough Innovation Report, released today, the findings highlight a number of leading trends that drinks manufacturers should be prepared to tap into in 2022 and beyond.
The report, which celebrates its 10th anniversary this year, has unveiled the leading innovations of the FMCG world that have made the biggest impact. The brands that made the list reflect a wide range of products and approaches that succeeded in making meaningful connections with consumers, an impressive feat within an increasingly crowded marketplace. With beverage launches accounting for over a third of Europe’s leading FMCG innovations, the winners highlight a further shift towards premiumisation in the drinks industry.
Leffe d'Été in France and Hansa Mango IPA in Norway achieved sales success by attracting new consumers into the brand and category, overcoming taste barriers associated with lager and IPA respectively.
Hansa Mango IPA, has been hugely successful in Norway after focusing on creating a beverage that is easy to drink by toning down on the natural bitter beer taste, particularly pertinent for IPA. Following extensive consumer testing, the team found that mango paired well with hopped IPA/beer and even improved the texture. Hansa Mango IPA also leveraged its retailer connections to secure strong listings with good visibility for the launch - critical in a country and category where advertising is banned. Initially intended as a limited summer edition, it is now a permanent product.
The launch of Martini Fiero offered consumers a new flavour profile and an easy to execute perfect serve to drive growth in the declining vermouth category, which was losing relevancy in Russia as consumers moved into modern aperitivo occasion. Bacardi identified an opportunity for Martini Fiero, a drink that is 100% natural in flavour and colour with a bittersweet, orange taste, to bring the vermouth category into this new occasion.
Shifting focus to the growing coffee market, Costa Coffee UK saw an opportunity to bring their out of home brand into consumers’ homes through entering the Ready-to-Drink category. The category was small but growing fast; Costa identified an opportunity to combine its coffee credentials and expertise to create a winning cold coffee proposition. The result was an RTD with authentic coffee flavour and less sugar than other products in the category.
Celine Grena, European BASES leader, comments: “Looking at this year’s winners, we can see a huge number of beverages leading the way for FMCG innovations. Taste remains one of the most important factors within the drinks category, with focus on the product development process playing a key role for the winners. It’s also worth noting that this strategy allows manufacturers to justify a premium, with nearly two-thirds of beverage winners premium to the category.”
Beverage Winners (listed in alphabetical order)
- Birra Messina Cristalli Di Sale (Italy)
- Costa Coffee Ready-to-Drink (UK)
- Hansa Mango IPA (Norway)
- Innocent Plus (UK & France)
- J.J Whitley – Artisanal Russian Vodka (UK)
- Leffe d'Été (France)
- Martini Fiero (Russia)
- Somersby Mango i Limonka (Poland)
- Starbucks for Nespresso (UK, France, Switzerland, Netherlands and Spain)
About NielsenIQ BASES Breakthrough Innovation
This year’s Breakthrough Innovation process reviewed over 50,000 product launches. The brands that made the 2021 list reflect a wide range of products and approaches that succeeded in making meaningful connections with consumers, an impressive feat within an increasingly crowded marketplace. Beyond BASES requirements for products that reflect strong, distinct qualities such as mass potential, longevity, brand incrementality, category distinction or appeal toward a specific consumer target, this year’s list brings the continued evolution of the success criteria, which includes all six of NielsenIQ BASES’ activation profiles.
About NielsenIQ
NielsenIQ is the leader in providing the most complete, unbiased view of consumer behavior, globally. Powered by a groundbreaking consumer data platform and fueled by rich analytic capabilities, NielsenIQ enables bold, confident decision-making for the world’s leading consumer goods companies and retailers.
Using comprehensive data sets and measuring all transactions equally, NielsenIQ gives clients a forward-looking view into consumer behavior in order to optimize performance across all retail platforms. Our open philosophy on data integration enables the most influential consumer data sets on the planet. NielsenIQ delivers the complete truth.
NielsenIQ, an Advent International portfolio company, has operations in nearly 100 markets, covering more than 90% of the world’s population. For more information, visit NielsenIQ.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211108006196/en/
Contact information
Publicasity
Gillian Mosher
NielsenIQ@publicasity.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
